A retrospective analysis from Israel suggested that markers of poor hydration are linked to increased risks of hypertension ...

Milestone Pharmaceuticals faces an FDA setback for its PSVT nasal spray. The company coordinates with regulatory authorities to resolve CRL issues.

Milestone Pharmaceuticals MIST recently announced that the FDA has issued a Complete Response Letter (“CRL”) for its New Drug Application (“NDA”) seeking approval for CARDAMYST (etripamil ...

In other recent news, Milestone Pharmaceuticals has encountered a setback with its New Drug Application for CARDAMYST™ (etripamil) nasal spray after receiving a Complete Response Letter from the FDA.

to $10 from $25 and keeps a Buy rating on the shares after Milestone announced that FDA issued a CRL for Cardamyst to request the company submit additional information on nitrosamine impurities ...

The facility changed ownership during the review of the NDA. “We are deeply disappointed by the CRL but remain committed to the potential of CARDAMYST as a novel treatment option that can help ...

(NASDAQ:MIST) shares plummeted 60% following a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning its New Drug Application (NDA) for CARDAMYST™ (etripamil) ...

Joe Oliveto, President and CEO of Milestone Pharmaceuticals, expressed disappointment over the CRL but reaffirmed the company’s commitment to CARDAMYST as a potential novel treatment for paroxysmal ...